# Viatris Inc: overview

VTRS · Nasdaq · CIK 1792044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vtrs.md) · [Financials](/companies/vtrs/financials.md) · [Filings](/companies/vtrs/filings.md) · [Insiders](/companies/vtrs/insiders.md)

Latest reported revenue: [$3.75bn](/filings/0001792044-26-000041.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001792044-26-000041).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,738](/filings/0001792044-25-000046.md) | [3,515 d](/filings/0001792044-26-000013.md) | [3,243](/filings/0001792044-26-000029.md) | [3,569](/filings/0001792044-26-000041.md) | [3,748](/filings/0001792044-25-000046.md) | [3,691 d](/filings/0001792044-26-000013.md) | [3,510](/filings/0001792044-26-000029.md) | [3,746](/filings/0001792044-26-000041.md) |
| Gross margin | % | [39.0%](/filings/0001792044-25-000046.md) | [34.6% d](/filings/0001792044-26-000013.md) | [35.8%](/filings/0001792044-26-000029.md) | [37.3%](/filings/0001792044-26-000041.md) | [36.6%](/filings/0001792044-25-000046.md) | [31.1% d](/filings/0001792044-26-000013.md) | [33.0%](/filings/0001792044-26-000029.md) | [38.9%](/filings/0001792044-26-000041.md) |
| Operating margin | % | [6.0%](/filings/0001792044-25-000046.md) | [(5.1%) d](/filings/0001792044-26-000013.md) | [(88.9%)](/filings/0001792044-26-000029.md) | [6.5%](/filings/0001792044-26-000041.md) | [4.8%](/filings/0001792044-25-000046.md) | [(5.2%) d](/filings/0001792044-26-000013.md) | [(2.3%)](/filings/0001792044-26-000029.md) | [0.2%](/filings/0001792044-26-000041.md) |
| Net margin | % | [2.5%](/filings/0001792044-25-000046.md) | [(14.7%) d](/filings/0001792044-26-000013.md) | [(93.8%)](/filings/0001792044-26-000029.md) | [(0.1%)](/filings/0001792044-26-000041.md) | [(3.4%)](/filings/0001792044-25-000046.md) | [(9.2%) d](/filings/0001792044-26-000013.md) | [5.0%](/filings/0001792044-26-000029.md) | [(3.2%)](/filings/0001792044-26-000041.md) |
| Diluted EPS | $ per share | [0.08](/filings/0001792044-25-000046.md) | not reported | [(2.55)](/filings/0001792044-26-000029.md) | [0.00](/filings/0001792044-26-000041.md) | [(0.11)](/filings/0001792044-25-000046.md) | not reported | [0.15](/filings/0001792044-26-000029.md) | [(0.10)](/filings/0001792044-26-000041.md) |
| Free cash flow | $m | [750 d](/filings/0001792044-25-000046.md) | [342 d](/filings/0001792044-26-000013.md) | [493](/filings/0001792044-26-000029.md) | [167 d](/filings/0001792044-26-000041.md) | [658 d](/filings/0001792044-25-000046.md) | [619 d](/filings/0001792044-26-000013.md) | [348](/filings/0001792044-26-000029.md) | [329 d](/filings/0001792044-26-000041.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [17.8](/filings/0001792044-24-000008.md) | [16.2](/filings/0001792044-25-000008.md) | [15.4](/filings/0001792044-26-000013.md) | [14.7](/filings/0001792044-26-000013.md) | [14.3](/filings/0001792044-26-000013.md) |
| Gross margin | % | [31.3%](/filings/0001792044-24-000008.md) | [40.1%](/filings/0001792044-25-000008.md) | [41.8%](/filings/0001792044-26-000013.md) | [38.3%](/filings/0001792044-26-000013.md) | [35.2%](/filings/0001792044-26-000013.md) |
| Operating margin | % | [(0.2%)](/filings/0001792044-24-000008.md) | [10.0%](/filings/0001792044-25-000008.md) | [5.0%](/filings/0001792044-26-000013.md) | [0.1%](/filings/0001792044-26-000013.md) | [(18.7%)](/filings/0001792044-26-000013.md) |
| Net margin | % | [(7.1%)](/filings/0001792044-24-000008.md) | [12.8%](/filings/0001792044-25-000008.md) | [0.4%](/filings/0001792044-26-000013.md) | [(4.3%)](/filings/0001792044-26-000013.md) | [(24.7%)](/filings/0001792044-26-000013.md) |
| Diluted EPS | $ per share | [(1.05)](/filings/0001792044-24-000008.md) | [1.71](/filings/0001792044-25-000008.md) | [0.05](/filings/0001792044-26-000013.md) | [(0.53)](/filings/0001792044-26-000013.md) | [(3.00)](/filings/0001792044-26-000013.md) |
| Free cash flow | $bn | [2.6](/filings/0001792044-24-000008.md) | [2.6](/filings/0001792044-25-000008.md) | [2.5](/filings/0001792044-26-000013.md) | [2.0](/filings/0001792044-26-000013.md) | [1.9](/filings/0001792044-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vtrs/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.53bn | 96,662,102 |  | Added +80,073,588 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.37bn | 86,019,468 |  | Added +1,659,664 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.21bn | 76,046,939 |  | Added +1,330,308 |
| [Davis Selected Advisers](/funds/1036325.md) | 2026-06-30 | $1.19bn | 75,232,254 |  | Reduced −2,978,937 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $862.0m | 54,282,080 |  | Added +370,843 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $842.7m | 53,069,461 |  | Added +835,762 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $542.6m | 34,168,743 |  | Added +668,743 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $520.1m | 32,807,906 |  | Added +961,799 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $476.0m | 29,970,094 |  | Reduced −8,340,599 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $329.8m | 20,771,275 |  | Reduced −1,197,382 |

## Recent filings

[All 533 filings](/companies/vtrs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-08 | 08:38 ET | [8-K](/filings/0001140361-26-039024.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-039024 |
| 2026-08-06 | 16:04 ET | [10-Q](/filings/0001792044-26-000041.md) | Quarterly report, period 2026-06-30 | 0001792044-26-000041 |
| 2026-08-06 | 07:56 ET | [8-K](/filings/0001792044-26-000037.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001792044-26-000037 |
| 2026-07-01 | 16:20 ET | [8-K](/filings/0001140361-26-027216.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001140361-26-027216 |
| 2026-06-18 | 16:10 ET | [8-K](/filings/0001140361-26-025744.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001140361-26-025744 |
| 2026-06-15 | 16:32 ET | [8-K](/filings/0001140361-26-025228.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-025228 |
| 2026-05-15 | 16:30 ET | [8-K](/filings/0001140361-26-021672.md) | 5.07 Shareholder vote results | 0001140361-26-021672 |
| 2026-05-07 | 16:03 ET | [10-Q](/filings/0001792044-26-000029.md) | Quarterly report, period 2026-03-31 | 0001792044-26-000029 |
| 2026-05-07 | 07:47 ET | [8-K](/filings/0001792044-26-000025.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001792044-26-000025 |
| 2026-05-04 | 16:39 ET | [8-K](/filings/0001140361-26-018887.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-018887 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001792044-26-000013.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/fb730faf-9f02-40a1-97b5-beb660e65ee0)

## About the filer

- CIK: 1792044
- Tickers: VTRS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:41 ET. No prices; not investment advice.